PhaseBio: Positive Results from Phase 2a Clinical Trial of PB2452
PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects June 17, 2019 16:01 ET | Source: PhaseBio…
Lumedica looks to fine-tune low-cost OCT system with SBIR grant
Duke University spin-out wins Phase II funding to further develop device for clinical applications in low-resource settings. Lumedica, the startup company spun out of co-founder Adam Wax’s Duke University research group, has won a $1 million…
NC startups raise $337M in Q2, lowest total in 3 years, but …
Led by 10 deals made in the Triangle, startups raised more than $337 million in the second quarter, the lowest total in three years, according to a new report from Dow Jones VemtureSource. But there…
“Deep Sepsis” Licensed to Cohere Med
Cohere Med licenses technology from Duke to drive adoption of early Sepsis detection using AI PRESS RELEASE: 3 JULY 2019 Sepsis strikes more than a million Americans every year and 15 to 30 percent…
Phitonex Launches NovaFluor Dyes Enabling High-Res Analysis
Phitonex, Inc. launched their new suite of NovaFluor dyes today at CYTO2019, the 34th Congress of the International Society for Advancement of Cytometry, the largest industry conference in single cell biology. New dyes developed on…
Infinia ML: 6 Papers Published for Machine Learning Conference
Infinia ML, an advanced machine learning company, announced today that members of its data science team collectively published six papers at the Thirty-sixth International Conference on Machine Learning, which takes place this week in Long…
Enzyvant Announces FDA Acceptance of Biologics License Application
Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia CAMBRIDGE, Mass. & BASEL, Switzerland–(BUSINESS WIRE)–Enzyvant, a biopharmaceutical company focused…
Enzyvant: FDA Acceptance of Biologics License Application
Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia —RVT-802, a one-time therapy, leverages Enzyvant’s T cell generation platform…
Amazon Prime Boss Named CEO of Google-Backed IonQ
Peter Chapman has had a varied career. The son of an astronaut, Chapman started programming at the Massachusetts Institute of Technology’s famed Artificial Intelligence Lab at the age of 16. He founded a company, Level Systems, that…